Corrigendum to "Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)" [Respir. Med. 170 (Aug-Sep 2020) 106021]

Respir Med. 2020 Dec:175:106186. doi: 10.1016/j.rmed.2020.106186. Epub 2020 Oct 18.

¹ Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany. Electronic address: [email protected].
² IKF Pneumologie Frankfurt, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany.
³ Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina.
⁴ Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa.
⁵ Institut für Allergie- und Asthmaforschung Berlin, IAAB, Germany.
⁶ Novartis Pharma AG, Basel, Switzerland.
⁷ Novartis Healthcare Pvt. Ltd, Hyderabad, India.
⁸ Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.

No abstract available

Publication types